Archive — US — techcrunch
Spore.Bio raises $23M to apply machine learning to microbiology testing
Spore.Bio, a Paris-based startup, raised $23 million in Series A funding to revolutionize microbiology testing using machine learning. Their technology reduces testing time from days to minutes, allowing on-site testing in factories. This innovation addresses contamination issues in the food, beverage, and pharmaceutical industries, with potential applications for environmentally friendly products. They aim to grow their team and expand operations significantly.
Key points
- 1. Spore.Bio raised $23 million in a Series A funding round led by Singular.
- 2. The startup's technology utilizes light and deep learning to detect bacteria in minutes.
- 3. Traditional microbiological tests take days, causing delays and potential contamination.
- 4. Spore.Bio has signed commercial contracts covering 200 factories.
- 5. Their partnership with the Pasteur Institute provides access to a biobank of bacteria samples.
- 6. A significant demand for on-site testing in various industries is driving their growth.
Why it matters
- The rise of deeptech companies leveraging AI for industry-specific applications aligns with current IT trends focusing on digitization and automation.
- The food safety crises have highlighted the need for rapid testing solutions, projecting a larger market for such technologies through 2025.
- Sustainable and preservative-free products are increasingly in demand, enhancing the relevance of Spore.Bio's solution in cosmetics and food sectors.
Spore.Bio's innovative approach to microbiology testing represents a significant advancement in food and health safety, meeting growing industry demands. Their funding success and technology promise to transform testing processes across multiple sectors, paving the way for quicker and safer product development.